IDH1 and IDH2 mutations are commonly found in low-grade glioma (70% of WHO grade 2 and 3 astrocytomas and oligodendrogliomas) and secondary GBM (which is developed from lower-grade gliomas). Here, IDH1 is linked to central nervous system cancer.